SuperworthEdwards Lifesciences Corporation EW
Medical - Devices, Healthcare
$85.78
−0.81%
- Market cap
- $49.4B
- PE
- 49.3×
- 10y median 40.5×
- Forward PE
- Price to sales
- 7.6×
- EV/EBIT
- 22.6×
- Revenue, 12 months
- $6.5B
- +15% on a year ago
- Net margin
- 15.4%
- Free cash flow yield
- 2.9%
Edwards Lifesciences trades at 49.3× trailing earnings, pricier than 69% of the last ten years. Revenue was $6.5B over the last twelve months, up 15% on a year earlier with a 15% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.3B | $1.3B | $1.4B | $1.4B | $1.4B+9% | $1.4B+6% | $1.5B+12% | $1.6B+15% | $1.6B+13% | $1.6B+17% | $1.7B+14% | |
| Cost of revenue | $251M | $286.9M | $275.5M | $262.9M | $292.2M+16% | $301.6M+5% | $344.4M+25% | $345.2M+31% | $343M+17% | $362.6M+20% | $392.4M+14% |
| Gross profit | $1B | $1B | $1.1B | $1.1B | $1.1B+8% | $1.1B+7% | $1.2B+9% | $1.2B+11% | $1.2B+12% | $1.3B+16% | $1.3B+14% |
| R&D | $242.1M | $256.7M | $271.8M | $253.4M | $271.1M+12% | $254.6M−1% | $276.2M+2% | $280.7M+11% | $267.7M−1% | $263.3M+3% | $278.9M+1% |
| SG&A | $416.6M | $428.4M | $447.5M | $421.4M | $491.9M+18% | $465.7M+9% | $502M+12% | $514.6M+22% | $602.9M+23% | $522.2M+12% | $561.2M+12% |
| $346.8M | $349M | $366.5M | $350.6M | $312.6M−10% | $394.8M+13% | $411.2M+12% | $307.1M−12% | $151.1M−52% | $477.6M+21% | $513.2M+25% | |
| Pre-tax income | $367.2M | $371.2M | $384M | $402.8M | $390.1M+6% | $433.9M+17% | $400.2M+4% | $348.4M−14% | $90.4M−77% | $459M+6% | $519.8M+30% |
| $34.1M | $46.3M | $20M | $40.7M | $45.1M+32% | $70.3M+52% | $64.3M+222% | $56.1M+38% | $26.2M−42% | $78.3M+11% | $278.4M+333% | |
| Net income | $369.9M | $351.9M | $366.3M | $3.1B | $385.6M+4% | $358M+2% | $333.2M−9% | $291.1M−91% | $91.2M−76% | $380.7M+6% | $241.9M−27% |
| $0.61 | $0.58 | $0.61 | $5.13 | $0.65+7% | $0.61+5% | $0.56−8% | $0.50−90% | $0.16−75% | $0.66+8% | $0.42−25% | |
| 606.9M | 604.1M | 604.3M | 598.1M | 590.5M−3% | 587.8M−3% | 587.9M−3% | 585.7M−2% | 581.8M−2% | 580.7M−1% | 577.6M−2% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Devices within ten times Edwards Lifesciences's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| EWEdwards Lifesciences Corporation | $49.4B | 49.3× | 40.5× | 7.6× | +15% | 15.4% | |
| BSXBoston Scientific Corporation | $60.3B | 16.8× | 66.3× | 2.9× | +14% | 17.5% | |
| DXCMDexCom, Inc. | $31.8B | 33.3× | 142× | 6.4× | +16% | 20.1% | |
| GEHCGE HealthCare Technologies Inc. | $29.2B | 18.7× | 19.9× | 1.4× | +7% | 9.3% | |
| SYKStryker Corporation | $105.6B | 28.5× | 41.2× | 4.1× | +8% | 14.4% | |
| MDTMedtronic plc | $109.4B | 21.1× | 28.4× | 2.9× | +10% | 13.9% | |
| ABTAbbott Laboratories | $170.8B | 31.8× | 36.2× | 3.7× | +8% | 11.6% | |
| Peer median | $82.9B | 24.8× | 38.7× | 3.3× | +9% | 14.2% |
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .